Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that the presentations of the MEDALIST and BELIEVE Phase 3 trial results of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) and beta-thalassemia associated anemias, respectively, were selected for “Best of ASH” by the American Society of Hematology at its 60th Annual Meeting & Exposition in San Diego. Luspatercept is an investigational therapy that is part of a global collaboration between Acceleron and Celgene.
The Society describes its “Best of ASH” selections, chosen from among the thousands of meeting abstracts, as “the biggest breakthroughs from the meeting’s scientific presentations.”
“Having both the MEDALIST and BELIEVE trials included in the Best of ASH session at the close of the annual meeting is extraordinarily gratifying,” said Habib Dable, President and Chief Executive Officer of Acceleron. “Throughout its development, luspatercept has demonstrated promising results in patients with these two distinct diseases associated with anemia. Yesterday’s event is a clear indication that the global hematology community recognizes the potential clinical impact of luspatercept.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.